Incyte will pay around $120 million upfront with an $80 million share buy-in to gain access to Netherlands biotech Merus and its preclinical Biclonics platform, sending Merus’ shares up 53% premark | Incyte will pay around $120 million upfront with an $80 million share buy-in to gain access to Netherlands biotech Merus and its preclinical Biclonics platform, sending Merus’ shares up 53% premarket on the news.
